The DOI matches its Crossref record; 65 of the 65 references it cites were found in a registry or an index.
Novel formulations of taxanes: a review. Old wine in a new bottle?
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Wani, M. C., Taylor, H. L., Wall, M. E., Coggon, P., & McPhail, A. T. (1971) · Journal of the American Chemical Society · doi:10.1021/ja00738a045 · Cited by 4,073
Promotion of microtubule assembly in vitro by taxol
SCHIFF, P. B., FANT, J., & HORWITZ, S. B. (1979) · Nature · doi:10.1038/277665a0 · Cited by 3,600
Gradishar, W. J., Tjulandin, S., Davidson, N., Shaw, H., Desai, N., Bhar, P., Hawkins, M., & O'Shaughnessy, J. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.937 · Cited by 2,153
Hypersensitivity reactions from taxol.
Weiss, R. B., Donehower, R. C., Wiernik, P. H., Ohnuma, T., Gralla, R. J., Trump, D. L., Baker, J. R., Van Echo, D. A., Von Hoff, D. D., & Leyland-Jones, B. (1990) · Journal of Clinical Oncology · doi:10.1200/jco.1990.8.7.1263 · Cited by 1,174
Kim, T.-Y., Kim, D.-W., Chung, J.-Y., Shin, S. G., Kim, S.-C., Heo, D. S., Kim, N. K., & Bang, Y.-J. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0655 · Cited by 821
In vivo evaluation of polymeric micellar paclitaxel formulation: toxicity and efficacy
Kim, S. C., Kim, D. W., Shim, Y. H., Bang, J. S., Oh, H. S., Kim, S. W., & Seo, M. H. (2001) · Journal of Controlled Release · doi:10.1016/s0168-3659(01)00275-9 · Cited by 734
Ibrahim, N. K., Desai, N. P., Legha, S. S., Soon‐Shiong, P., Theriault, R. L., Rivera, E., Esmaeli, B., Ring, S. E., Bedikian, A. Y., Hortobágyi, G. N., et al. (2002) · PubMed · Cited by 705
Clinical toxicities encountered with paclitaxel (Taxol).
Rowinsky, E. K., Eisenhauer, E. A., Chaudhry, V., Sg, A., & Rc, D. (1993) · PubMed · Cited by 692
Pharmacological Effects of Formulation Vehicles: Implications for Cancer Chemotherapy
ten Tije, A. J., Verweij, J., Loos, W. J., & Sparreboom, A. (2003) · Clinical Pharmacokinetics · doi:10.2165/00003088-200342070-00005 · Cited by 591
Central Nervous System Toxicity after Liver Transplantation
de Groen, P. C., Aksamit, A. J., Rakela, J., Forbes, G. S., & Krom, R. A. F. (1987) · New England Journal of Medicine · doi:10.1056/nejm198710013171404 · Cited by 498
Phase I clinical and pharmacokinetic study of taxol.
Wiernik, P. H., Schwartz, E. L., Strauman, J. J., Dutcher, J. P., Lipton, R. B., & Paietta, E. M. (1987) · PubMed · Cited by 455
Green, M. C., Buzdar, A. U., Smith, T., Ibrahim, N. K., Valero, V., Rosales, M. F., Cristofanilli, M., Booser, D. J., Pusztai, L., Rivera, E., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.06.232 · Cited by 419
Poly(l-glutamic acid)–anticancer drug conjugates
Li, C. (2002) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(02)00045-5 · Cited by 414
Li, C., Yu, D. F., Newman, R. A., Cabral, F., Stephens, L. C., Hunter, N. R., Milas, L., & Wallace, S. (1998) · PubMed · Cited by 340
(1999) · PubMed · Cited by 337
Sparreboom, A., van Tellingen, O., Nooijen, W. J., & Beijnen, J. H. (1996) · PubMed · Cited by 313
Role of Formulation Vehicles in Taxane Pharmacology
van Zuylen, L., Verweij, J., & Sparreboom, A. (2001) · Investigational New Drugs · doi:10.1023/a:1010618632738 · Cited by 293
Winer, E. P., Berry, D. A., Woolf, S., Duggan, D., Kornblith, A., Harris, L. N., Michaelson, R. A., Kirshner, J. A., Fleming, G. F., Perry, M. C., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.08.048 · Cited by 270
The taxoids: paclitaxel and docetaxel
Gelmon, K. (1994) · The Lancet · doi:10.1016/s0140-6736(94)90754-4 · Cited by 243
Lorenz, W., Reimann, H. J., Schmal, A., Dormann, P., Schwarz, B., Neugebauer, E., & Doenicke, A. (1977) · Agents and Actions · doi:10.1007/bf01964882 · Cited by 219
Cremophor EL causes (pseudo-) non-linear pharmacokinetics of paclitaxel in patients
Tellingen, O. V., Huizing, M. T., Panday, V. R. N., Schellens, J. H. M., Nooijen, W. J., & Beijnen, J. H. (1999) · British Journal of Cancer · doi:10.1038/sj.bjc.6690696 · Cited by 211
van Asperen, J., van Tellingen, O., Sparreboom, A., Schinkel, A., Borst, P., Nooijen, W., & Beijnen, J. (1997) · British Journal of Cancer · doi:10.1038/bjc.1997.530 · Cited by 202
Chaj�s, V., Sattler, W., Stranzl, A., & Kostner, G. M. (1995) · Breast Cancer Research and Treatment · doi:10.1007/bf00689711 · Cited by 198
Tumor targeting by covalent conjugation of a natural fatty acid to paclitaxel.
Bradley, M. O., Webb, N. L., Anthony, F. H., Devanesan, P. D., Witman, P. A., Hemamalini, S., Chander, M. C., Baker, S. D., He, L., Horwitz, S. B., et al. (2001) · PubMed · Cited by 180
Singer, J. W., Baker, B., de Vries, P., Kumar, A., Shaffer, S., Vawter, E., Bolton, M., & Garzone, P. D. (2004) · Advances in experimental medicine and biology · doi:10.1007/0-306-47932-x_6 · Cited by 168
Woodcock, D. M., Jefferson, S., Linsenmeyer, M. E., Crowther, P. J., Chojnowski, G. M., Williams, B. T., & Bertoncello, I. (1990) · PubMed · Cited by 168
DAMASCELLI, B., Cant�, G., Mattavelli, F., Tamplenizza, P., Bidoli, P., Leo, E., Dosio, F., Cerrotta, A., Tolla, G. D., Frigerio, L. F., et al. (2001) · Cancer · Cited by 146
Phytochrome and Photomorphogenesis in Plants
Smith, H. (1970) · Nature · doi:10.1038/227665a0 · Cited by 128
Sabbatini, P. J., Aghajanian, C. A., Dizon, D. S., Anderson, S., Dupont, J., Brown, J. V., Peters, W. A., Jacobs, A. D., Mehdi, A., Rivkin, S. E., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.12.043 · Cited by 125
Risks and Benefits of Taxanes in Breast and Ovarian Cancer
Michaud, L. B., Valero, V., & Hortobágyi, G. N. (2000) · Drug Safety · doi:10.2165/00002018-200023050-00005 · Cited by 121
Harper, E., Dang, W., Lapidus, R. G., & Garver, R. I. (1999) · PubMed · Cited by 120
Antitumor activity of poly(L-glutamic acid)-paclitaxel on syngeneic and xenografted tumors.
Li, C., Price, J. E., Milas, L., Hunter, N. R., Shi, K., Yu, D. F., Charnsangavej, C., & Wallace, S. (1999) · PubMed · Cited by 114
van Tellingen, O., Beijnen, J. H., Verweij, J., Scherrenburg, E. J., Nooijen, W. J., & Sparreboom, A. (1999) · PubMed · Cited by 113
Anti-tumor efficacy and biodistribution of intravenous polymeric micellar paclitaxel
Zhang, X., Burt, H. M., Mangold, G., Dexter, D. L., Hoff, D. D. V., Mayer, L. D., & Hunter, W. L. (1997) · Anti-Cancer Drugs · doi:10.1097/00001813-199708000-00008 · Cited by 112
Clinical pharmacokinetics of unbound docetaxel: role of polysorbate 80 and serum proteins
Loos, W. J. (2003) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(03)00222-4 · Cited by 109
An investigation of the antitumour activity and biodistribution of polymeric micellar paclitaxel
Zhang, X., Burt, H. M., Hoff, D. D. V., Dexter, D. L., Mangold, G., Degen, D. R., Oktaba, A. M., & Hunter, W. L. (1997) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s002800050630 · Cited by 108
Potential neurotoxicity of the solvent vehicle for cyclosporine.
Windebank, A. J., Blexrud, M. D., & de Groen, P. C. (1994) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)38962-7 · Cited by 105
Comparative in vivo studies with paclitaxel and liposome-encapsulated paclitaxel.
Cabanes, A., Briggs, K., Gokhale, P. C., Treat, J., & Rahman, A. (1998) · International Journal of Oncology · doi:10.3892/ijo.12.5.1035 · Cited by 103
Liebmann, J., Cook, J. A., Lipschultz, C. A., Teague, D., Fisher, J. M., & Mitchell, J. B. (1994) · Cancer Chemotherapy and Pharmacology · doi:10.1007/bf00685909 · Cited by 102
Li, C., Shi, K., Wu, Q., Tansey, W., Hunter, N. R., Buchmiller, L., Milas, L., Charnsangavej, C., & Wallace, S. (2000) · PubMed · Cited by 102
Progress in the Development of Alternative Pharmaceutical Formulations of Taxanes
Nuijen, B., Bouma, M., Schellens, J. H. M., & Beijnen, J. H. (2001) · Investigational New Drugs · doi:10.1023/a:1010682916808 · Cited by 96
Phase I and Pharmacokinetic Study of Oral Paclitaxel
Malingré, M. M., Terwogt, J. M. M., Beijnen, J. H., Rosing, H., Koopman, F. J., van Tellingen, O., Duchin, K., Huinink, W. W. T. B., Swart, M., Lieverst, J. A., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.12.2468 · Cited by 96
Clinical Evidence for Topotecan-Paclitaxel Non–Cross-Resistance in Ovarian Cancer
Gore, M. E., Huinink, W. W. T. B., Carmichael, J., Gordon, A. N., Davidson, N. G. P., Coleman, R. E., Spaczyński, M., Héron, J., Bolis, G., Malmström, H., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.7.1893 · Cited by 92
Onetto-Pothier, N., Canetta, R. M., Winograd, B., Catane, R., Dougan, M., Grechko, J., Burroughs, J., & Rozencweig, M. (1993) · PubMed · Cited by 92
Shionoya, M., Jimbo, T., Kitagawa, M., Soga, T., & Tohgo, A. (2003) · Cancer Science · doi:10.1111/j.1349-7006.2003.tb01465.x · Cited by 85
Wolff, A. C., Donehower, R. C., Carducci, M., Carducci, M. A., Brahmer, J. R., Zabelina, Y., Bradley, M. O., Anthony, F. H., Swindell, C. S., Witman, P. A., et al. (2003) · PubMed · Cited by 80
DAMASCELLI, B., Patelli, G., Lanocita, R., Tolla, G. D., Frigerio, L. F., Marchianò, A. V., Garbagnati, F., Spreafico, C., Tichà, V., Regna‐Gladin, C., et al. (2003) · American Journal of Roentgenology · doi:10.2214/ajr.181.1.1810253 · Cited by 77
Is Cremophor EL, solvent for paclitaxel, cytotoxic?
Fjällskog, M.-L., Frii, L., & Bergh, J. C. S. (1993) · The Lancet · doi:10.1016/0140-6736(93)92735-c · Cited by 76
Polilactofate microspheres for Paclitaxel delivery to central nervous system malignancies.
Li, K. W., Dang, W., Tyler, B., Troiano, G., Tihan, T., Brem, H., & Walter, K. A. (2003) · PubMed · Cited by 65
The polyoxyethylene castor oil Cremophor EL modifies multidrug resistance
Schuurhuis, G. J., Broxterman, H. J., Pinedo, H. M., van Heijningen, T. H. M., van Kalken, C. K., Vermorken, J. B., Spoelstra, E. C., & Lankelma, J. (1990) · British Journal of Cancer · doi:10.1038/bjc.1990.335 · Cited by 63
Synthesis and Antitumor Activity of Novel C-7 Paclitaxel Ethers: Discovery of BMS-184476
Altstadt, T. J., Fairchild, C. R., Golik, J., Johnston, K., Kadow, J. F., Lee, F. Y., Long, B. H., Rose, W. C., Vyas, D. M., Wong, H., et al. (2001) · Journal of Medicinal Chemistry · doi:10.1021/jm0102607 · Cited by 59
Polymer Drugs in the Clinical Stage
Maeda, H., Okano, T., Kataoka, K., & Kabanov, A. Y. (2003) · Advances in experimental medicine and biology · doi:10.1007/b105364 · Cited by 57
Kimura, Y. (2002) · Journal of Nutrition · doi:10.1093/jn/132.7.2069 · Cited by 55
Sparreboom, A., Wolff, A. C., Verweij, J., Zabelina, Y., van Zomeren, D. M., McIntire, G. L., Swindell, C. S., Donehower, R. C., & Baker, S. D. (2003) · PubMed · Cited by 52
Preclinical antitumor activity of two novel taxanes
Rose, W. C., Fairchild, C. A., & Lee, F. Y. F. (2001) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s002800000241 · Cited by 48
Hidalgo, M. M., Aylesworth, C. A., Hammond, L. A., Britten, C. D., Weiss, G. R., Stephenson, J., Schwartz, G. H., Patnaik, A., Smith, L. S., Molpus, K., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.9.2493 · Cited by 42
Cassinelli, G., Lanzi, C., Supino, R., Pratesi, G., Zuco, V., Laccabue, D., Cuccuru, G., Bombardelli, E., & Zunino, F. (2002) · PubMed · Cited by 39
Brat, D. J., Aj, W., & Brimijoin, S. (1992) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)11107-5 · Cited by 38
Treat, J., Damjanov, N., Huang, C., Zrada, S., & Rahman, A. (2001) · PubMed · Cited by 35
Docetaxel as an Alternative to Paclitaxel After Acute Hypersensitivity Reactions
Bernstein, B. J. (2000) · Annals of Pharmacotherapy · doi:10.1345/aph.19383 · Cited by 34
Js, K., Amorino, G. P., Pyo, H., Cao, Q., Price, J. O., & Choy, H. (2001) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(01)01658-3 · Cited by 30
Fjällskog, M.-L., Frii, L., & Bergh, J. C. S. (1994) · European Journal of Cancer · doi:10.1016/0959-8049(94)90546-0 · Cited by 30
Langer, C. J., Socinski, M. A., & O'Byrne, K. J. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.23.16_suppl.lba7011 · Cited by 28
Harries, M., O’Donnell, A. E., Scurr, M. R., Reade, S., Cole, C., Judson, I. R., Greystoke, A., Twelves, C. J., & Kaye, S. B. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6602196 · Cited by 27
LEWIN, R., HART, H. E., GREENBERG, J., et al. (1954) · PubMed · Cited by 19
Cited by
Insoluble drug delivery strategies: review of recent advances and business prospects
Kalepu, S., & Nekkanti, V. (2015) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2015.07.003 · Cited by 1,410
Natural compounds for cancer treatment and prevention
Nobili, S., Lippi, D., Witort, E., Donnini, M., Bausi, L., Mini, E., & Capaccioli, S. (2009) · Pharmacological Research · doi:10.1016/j.phrs.2009.01.017 · Cited by 780
Lee, K. S., Chung, H. C., Im, S. A., Park, Y. H., Kim, C. S., Kim, S.-B., Rha, S. Y., Lee, M. Y., & Ro, J. (2008) · Breast Cancer Research and Treatment · doi:10.1007/s10549-007-9591-y · Cited by 541
“Given the drawbacks resulting from the use of CrEL as a solubilizer, new CrEL-free formulations of paclitaxel are of great interest for development in clinical use [9].”
BackgroundTalelli, M., Barz, M., Rijcken, C. J. F., Kiessling, F., Hennink, W. E., & Lammers, T. (2015) · Nano Today · doi:10.1016/j.nantod.2015.01.005 · Cited by 506
Gubernator, J. (2011) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2011.566552 · Cited by 325
Metadata
- Authors
- Hennenfent, K. L., & Govindan, R.
- Venue
- Annals of Oncology
- Publisher
- Elsevier BV
- Published
- 2006-05
- Volume
- 17
- Issue
- 5
- Pages
- 735-749
- ISSN
- 0923-7534 (ISSN-L)
- OpenAlex
- W2136447069
- Cited by
- 345
- References
- 65
- FWCI
- 5.23
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.